Older adults prescribed stimulant medications for ADHD face a 40% higher risk of stroke, heart attack, or ventricular arrhythmia in the first month of treatment, a detail that has been quietly sitting in medical literature while millions of new prescriptions are written every year. That figure doesn’t apply to a fringe group or a high-risk outlier. It applies to the same medications, Ritalin, Adderall, Concerta, that doctors now prescribe to a rapidly expanding population of adults who received their diagnoses well into middle age or beyond.
The ADHD medication cardiac risks conversation is not new, but the scale of the population now exposed to it is. For decades, stimulant safety research focused on children. What’s shifted dramatically is who is actually taking these drugs. A generation of adults who grew up before widespread ADHD awareness are now receiving diagnoses and starting stimulant therapy in their 40s, 50s, and 60s, an age at which baseline cardiovascular risk is meaningfully higher than it was in any pediatric trial.
Stimulant medications are being prescribed to older adults more frequently, and some research shows they may contribute to a short-term rise in the risk of heart attack, stroke, and other cardiac problems. Whether the risk is clinically significant at the population level, manageable with monitoring, or concentrated in specific subgroups is the question that researchers, cardiologists, and patients are now grappling with, and the answers are more layered than most headlines suggest.
ADHD Diagnoses Are Climbing Fast
According to data compiled by The World Data, approximately 7 million children ages 3 – 17 in the US had a current ADHD diagnosis in 2022, representing 11% of that age group, roughly 1 million more than in 2016. That rise among children, though notable, is modest compared to what’s happened in the adult population.
By late 2023, an estimated 15.5 million US adults, about 6% of the adult population, had a current ADHD diagnosis, nearly double the 2018 estimate. A significant part of that surge is explained by a structural shift in who gets diagnosed. Over half of all adults with a current ADHD diagnosis received their formal diagnosis in adulthood, according to data from The World Data, a historic departure from the traditional model of childhood identification.
The treatment pattern follows the diagnosis trend. Stimulants are the dominant therapy class, with amphetamines documented in 41.7% of adult health center visits for ADHD, making them the most common medication prescribed. That means millions of adults, many of them newly diagnosed and older, are starting stimulant therapy without the decades of pediatric safety data that informed earlier prescribing norms.
What Stimulants Actually Do to the Heart
Stimulant medications work by increasing dopamine and norepinephrine in the brain. The same mechanism that sharpens focus also puts upward pressure on the cardiovascular system. A 2022 review published in Frontiers in Neuroscience found that stimulant ADHD medications increase heart rate by 4 – 5 beats per minute on average. Mixed amphetamine salts administered to adults have been shown to increase systolic blood pressure by about 5 mm Hg, according to a perspective published in The New England Journal of Medicine.
Neither of those numbers sounds alarming in isolation. A resting heart rate bumped up by four beats and a systolic reading five points higher are the kinds of changes most people wouldn’t feel. But sustained elevations in blood pressure and heart rate, maintained over years, are exactly the profile that cardiovascular medicine identifies as drivers of long-term disease, particularly hypertension, arrhythmia, and stroke.
A study published in European Heart Journal – Cardiovascular Pharmacotherapy found that methylphenidate use is associated with increased risk of out-of-hospital cardiac arrest in the general population. A separate analysis found a 1.8-fold increased risk of sudden death or ventricular arrhythmia linked to methylphenidate use in some study populations, according to a cardiac risks review.
The picture across specific drugs isn’t uniform. A 2024 analysis using the WHO pharmacovigilance database found that amphetamines posed the highest cardiovascular risk among ADHD medications, while lisdexamfetamine and methylphenidate showed better safety profiles. Heart failure, stroke, and cardiac death were exclusively associated with amphetamines in that analysis. Lisdexamfetamine, a prodrug that converts to amphetamine more slowly in the body, showed a weaker cardiovascular signal than standard amphetamines, and methylphenidate showed the lowest overall association.
The Long-Term Risk Picture
Short-term blood pressure and heart rate changes are one concern. What happens after years of use is another, and here the evidence is growing more pointed.
Research reported by The Cardiology Advisor found that long-term ADHD treatment increases risk for stroke, heart failure, and other cardiovascular outcomes over 10 years, with higher risk observed at higher dosages. The underlying study used Danish nationwide health registers covering adults who initiated ADHD treatment between 1998 and 2020. Adults receiving ADHD treatment for the first time showed an increased 10-year risk for stroke, heart failure, and a composite cardiovascular outcome, with a higher risk at higher dosage, according to a study in the Journal of the American College of Cardiology.
A large Swedish study tracking over 278,000 individuals with ADHD over 13 years produced similar findings. Researchers found that the longer an individual used ADHD medication, the higher their risk of developing cardiovascular disease compared to those who did not take ADHD medication, with each additional year of use associated with an average 4% increase in heart disease risk. Overall, heart disease risk was 23% higher for people who used ADHD medication for more than five years compared to those who never used it.
A 2024 Swedish study using methylphenidate-treated individuals found a 10% higher cardiovascular event rate compared with matched non-treated controls over a six-month observation window. Long-term use of ADHD medication was also associated with increased risk of hypertension, the most common cardiovascular outcome in the dataset, with a nearly 80% higher risk after more than five years of use.
The Older Adult Problem
The majority of ADHD cardiovascular research was conducted on younger populations. That makes the adult, and especially older adult, data particularly important, because baseline cardiovascular risk rises with age.
A 2026 study published in Pharmacoepidemiology and Drug Safety found that older adults initiating methylphenidate had a 73% higher risk of serious cardiovascular events compared to those initiating amphetamine. That finding reverses the general assumption that methylphenidate is the safer option, and shows how much the risk profile can shift with age and medication class.
A separate 2026 analysis also found that amphetamine initiation in adults over 66 was independently associated with a 73% increased hazard of major adverse cardiovascular events. When both drugs carry that kind of signal in older adults, the decision to prescribe becomes significantly more complex than it was when the target patient was a seven-year-old with hyperactivity.
Read More: ADHD in Adults: Signs, Symptoms, and What to Do Next
The Condition Itself May Carry Independent Risk
One important complication in interpreting all of this research: ADHD itself may raise cardiovascular risk, independent of the medications used to treat it.
Adults with ADHD may be twice as likely to develop cardiovascular diseases, according to a large population-based study in Sweden. In a study published in World Psychiatry, researchers collected data on more than 5 million adults, 37,000 of whom had ADHD. During an average 12-year follow-up, 38% of those with ADHD developed cardiovascular disease, compared with 23.5% of those without it.
ADHD appears to increase the risk for both coronary artery disease and heart failure, according to research published in Twin Research and Human Genetics in January 2026. The authors identified a genetic component: certain genes that raise ADHD risk also appear to raise cardiovascular risk independently. Behavioral factors also play a role – impulsivity, poor diet maintenance, disrupted sleep, and higher rates of smoking are all more common in people with ADHD and all contribute to heart disease risk.
This doesn’t mean that cardiovascular risk in people with ADHD is purely a medication problem. But it does mean that the population starting stimulant therapy may already carry a higher-than-average cardiac burden before the first pill is taken.
What the Reassuring Evidence Says
The science on ADHD medication cardiac risks is not one-directional. Some large studies have found no significant increase in serious cardiovascular events among users.
A meta-analysis of 11 studies including over 3.1 million people with no prior history of cardiovascular disease found no association between ADHD medications and cardiovascular events. A 2025 systematic review and network meta-analysis published in The Lancet Psychiatry, led by Professor Samuele Cortese at the University of Southampton, found that ADHD medications are associated with only small increases in blood pressure and heart rate in both children and adults, and that cardiovascular risks are relatively minor in the short term.
Cortese himself acknowledged that while findings hold “at the group level,” they “cannot exclude that a subgroup of individuals may have a higher risk of more substantial cardiovascular alterations.” That caveat matters. Population-level reassurance doesn’t cancel individual-level risk, particularly for patients who are older, have pre-existing hypertension, or are taking higher doses for extended periods.
Regulators Have Flagged This Before
The cardiovascular concerns around ADHD drugs have a regulatory history that stretches back two decades. In 2006, an FDA Drug Safety and Risk Management Advisory Committee voted 8 to 7 to recommend a black-box warning on ADHD medications describing cardiovascular risks. The FDA did not ultimately require the black-box label, but it did act the following year. In 2007, US health officials told manufacturers of all drugs used to treat ADHD they must develop patient medication guides warning of cardiovascular and psychiatric risks.
Those warnings remain in place. What’s changed is that the population they apply to has grown enormously, and now includes many patients who were never part of the original risk discussions that prompted the warnings.
What to Do If You or Someone You Know Takes These Medications
Anyone currently prescribed a stimulant medication for ADHD, or considering starting one, should have an explicit conversation with their doctor about cardiovascular baseline. That means blood pressure measured before starting treatment, with follow-up readings during the first weeks. Patients over 50, those with pre-existing hypertension, or anyone with a family history of early heart disease fall into a higher-scrutiny category and should ask specifically about non-stimulant alternatives such as atomoxetine, clonidine, or guanfacine. The Lancet Psychiatry research team noted that practitioners should monitor blood pressure and pulse in patients with ADHD treated with any pharmacological intervention, not only those on stimulants.
The dose question is also worth raising directly. Research suggests that patients taking at least one defined daily dose per day showed higher 10-year absolute risks of stroke (2.1% vs. 1.7%) and heart failure (1.2% vs. 0.7%) compared to lower-dose users. The practical implication: the lowest effective dose is not just a general principle of cautious prescribing. In this context, it may carry meaningful cardiovascular weight.
The broader message is that ADHD medication, for many people, carries real and manageable benefits that outweigh risks. The problem isn’t the medication class; it’s the lack of structured cardiovascular monitoring for a patient population that has grown far faster than the clinical protocols designed to protect it. Researchers on the long-term Danish study concluded that greater attention to cardiovascular risk factors at the start of treatment, and to cardiovascular symptoms during treatment, may be warranted in patients with ADHD, with particular focus on those taking a higher dosage for extended periods. That’s advice that applies to any prescriber writing a stimulant script today.
Disclaimer: The author is not a licensed medical professional. The information provided is for general informational and educational purposes only and is based on research from publicly available, reputable sources. It is not intended to constitute, and should not be relied upon as, medical advice, diagnosis, or treatment. Always consult a licensed physician or other qualified healthcare provider regarding any medical condition, symptoms, or medications. Do not disregard, avoid, or delay seeking professional medical advice or treatment because of information contained herein.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: How ADHD May Influence Creative Thinking, According To New Research